BIIB - Biogen Inc.
| Previous Close | 232.06 |
| Open | 231.26 |
| Bid | 225.15 x 900 |
| Ask | 229.00 x 1000 |
| Day's Range | 225.11 - 231.53 |
| 52 Week Range | 216.12 - 358.41 |
| Volume | 1,288,061 |
| Avg. Volume | 1,446,804 |
| Market Cap | 41.657B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | 8.42 |
| EPS (TTM) | 26.83 |
| Earnings Date | Oct 21, 2019 - Oct 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 258.00 |
- Simply Wall St.
Could The Biogen Inc. (NASDAQ:BIIB) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Biogen Inc. (NASDAQ:BIIB) have power over the company. Insiders often own a large chunk...
- MoneyShow
Biogen- Buybacks and Biotech
Biogen (BIIB) is a major biopharmaceutical company specializing in treatments for multiple sclerosis (about 60% of sales) and spinal muscular atrophy (about 15% of sales), notes George Putnam, editor of The Turnaround Letter.
- GlobeNewswire
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
SMA Identified program offers genetic testing for SMA at no charge to individuals in the U.S. CAMBRIDGE, Mass. and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) and Invitae Corporation (NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease.
- Zacks
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
- Zacks
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Are Investors Undervaluing Biogen (BIIB) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Mergers & Acquisitions Take Center Stage in Biotech Industry
Mergers & Acquisitions Take Center Stage in Biotech Industry
- Zacks
Top Ranked Momentum Stocks to Buy for August 12th
Top Ranked Momentum Stocks to Buy for August 12th
- Zacks
5 ROE Stocks to Profit as Trade War Spurs Volatility
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
- Zacks
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
- Zacks
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
- American City Business Journals
Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy
After years as a rare disease drugmaker, Sarepta Therapeutics Inc. is expanding into a neurological disease that affects millions of people worldwide and has been dominated for years by its Cambridge neighbor, Biogen Inc.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Thomson Reuters StreetEvents
Edited Transcript of BIIB earnings conference call or presentation 23-Jul-19 12:00pm GMT
Q2 2019 Biogen Inc Earnings Call
- Zacks
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
- Zacks
Top Ranked Momentum Stocks to Buy for August 2nd
Top Ranked Momentum Stocks to Buy for August 2nd
- American City Business Journals
5 years later, Ice Bucket Challenge's impact on drug research still unfolding
The challenge raised a "mind-boggling" amount of money for ALS research, but those funds were quickly spent.
- American City Business Journals
Biogen on the brink: One of the state's largest drugmakers faces a crisis
Sure, the Cambridge biotech giant Biogen has stumbled and recovered before. But the question now on many people’s minds is whether CEO Michel Vounatsos can revive the company yet again.
- MoneyShow
Biogen- A Biotech Buyback Bet
We last held shares of Biogen Idec Inc. (BIIB) in 2010; the biotech company is known for selling drugs and therapies to combat many degenerative nerve diseases, blood conditions and autoimmune diseases, notes David Fried, editor of The Buyback Letter.
- Morningstar
Long-Term Outperformance Is the Norm at This Large-Cap Fund
The following is our latest Fund Analyst Report for PRIMECAP Odyssey Stock POSKX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Primecap Odyssey Stock retains a Morningstar Analyst Rating of Gold.
- Simply Wall St.
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
3 Reasons Growth Investors Will Love Biogen (BIIB)
Biogen (BIIB) could produce exceptional returns because of its solid growth attributes.
